Ito K - Search Results

1

Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.

Ito K, Houston JB. Ito K, et al. Pharm Res. 2005 Jan;22(1):103-12. doi: 10.1007/s11095-004-9015-1. Pharm Res. 2005. PMID: 15771236

2

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. Ito K, et al. AAPS PharmSci. 2002;4(4):E25. doi: 10.1208/ps040425. AAPS PharmSci. 2002. PMID: 12645997 Free PMC article.

3

Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.

Ito K, Ogihara K, Kanamitsu S, Itoh T. Ito K, et al. Drug Metab Dispos. 2003 Jul;31(7):945-54. doi: 10.1124/dmd.31.7.945. Drug Metab Dispos. 2003. PMID: 12814973

4

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

Ito K, Brown HS, Houston JB. Ito K, et al. Br J Clin Pharmacol. 2004 Apr;57(4):473-86. doi: 10.1111/j.1365-2125.2003.02041.x. Br J Clin Pharmacol. 2004. PMID: 15025746 Free PMC article. Review.

5

Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Ito K, Houston JB. Ito K, et al. Pharm Res. 2004 May;21(5):785-92. doi: 10.1023/b:pham.0000026429.12114.7d. Pharm Res. 2004. PMID: 15180335

6

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

Galetin A, Brown C, Hallifax D, Ito K, Houston JB. Galetin A, et al. Among authors: ito k. Drug Metab Dispos. 2004 Dec;32(12):1411-20. doi: 10.1124/dmd.104.000844. Epub 2004 Sep 1. Drug Metab Dispos. 2004. PMID: 15342470

7

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Galetin A, Ito K, Hallifax D, Houston JB. Galetin A, et al. Among authors: ito k. J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. doi: 10.1124/jpet.104.082826. Epub 2005 Mar 22. J Pharmacol Exp Ther. 2005. PMID: 15784650 Free article.

8

Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.

Ito K, Hallifax D, Obach RS, Houston JB. Ito K, et al. Drug Metab Dispos. 2005 Jun;33(6):837-44. doi: 10.1124/dmd.104.003715. Drug Metab Dispos. 2005. PMID: 15897600

9

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Brown HS, Ito K, Galetin A, Houston JB. Brown HS, et al. Among authors: ito k. Br J Clin Pharmacol. 2005 Nov;60(5):508-18. doi: 10.1111/j.1365-2125.2005.02483.x. Br J Clin Pharmacol. 2005. PMID: 16236041 Free PMC article.

10

Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. Hakooz N, et al. Among authors: ito k. Pharm Res. 2006 Mar;23(3):533-9. doi: 10.1007/s11095-006-9531-2. Epub 2006 Feb 28. Pharm Res. 2006. PMID: 16505976

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results